Skip to main content
. 2021 Jan 27;12:608. doi: 10.1038/s41467-020-20801-0

Fig. 5. Ntn1 preserves HSC quiescence and engraftment potential in vitro via Neo1.

Fig. 5

a Workflow: In vitro stimulation of sorted HSCs used in (b–d), analysis after 48 h. b Relative expression of Egr1 in Wt HSCs; n = 3 (other), 4 (RGM-a + b), 16 (Ctrl/Neo1), for ctrl/Ntn1, four independent experiments. c Representative cell cycle plots pre-gated on HSCs and quantification with or without Ntn1 treatment; n = 3 (Neo1), 11 (Wt-Ctrl), 12 (Wt-Ntn1), three independent experiments for ctrl HSC. d MFI of CDK6 in Wt HSCs 48 h after Ntn1 treatment, quantification of MFI per cell; n = 114 (Ctrl) and 134 (Ntn1). e Workflow: representative images and quantification of total cell/nuclear MFI of p65-GFP HSC 48 h after treatment with Ntn1 or Ntn1 + JSH-23; n = 8 (JSH-23), 78 (Ctrl), 91 (Ntn1), two independent experiments. f Workflow: competitive transplantation of Ntn1 stimulated CD45.2 and CD45.1/2 HSCs. g Chimerism of bone marrow LSK-SLAM cells 4 months after competitive transplantation of Control vs. Ntn1-treated HSCs; n = 6 (CD45.1/2), 7 (CD45.2), two independent experiments. For all panels, ±SD is shown. n indicates biological replicates. Scale bars in IF images are 4 μm. P value was determined by two-tailed t test unless stated otherwise. Source data are provided as a Source Data file.